AMRX vs HAL · P/E 44, rev $2.79B vs P/E 9.3, $19.05B cap
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Halliburton Company (HAL) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Halliburton Company (HAL) is a oil & gas equipment & services company listed on US.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
HAL does not have a complete income-statement cache yet.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. HAL currently screens at market cap $19.05B and trailing P/E 9.3.
Not investment advice. Open the AMRX and HAL stock pages for the full models.
Not investment advice.